Avadel Pharmaceuticals plc (AVDL)
$2.31
-0.12 (-4.94%)
Rating:
Recommendation:
Buy
| Symbol | AVDL |
|---|---|
| Price | $2.31 |
| Beta | 1.170 |
| Volume Avg. | 3.97M |
| Market Cap | 136.378M |
| Shares () | - |
| 52 Week Range | 1.05-11.59 |
| 1y Target Est | - |
| DCF Unlevered | AVDL DCF -> | |
|---|---|---|
| DCF Levered | AVDL LDCF -> | |
| ROE | -102.82% | Strong Sell |
| ROA | -40.84% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 300.36% | Strong Buy |
| P/E | - | |
| P/B | 2.46 | Strong Buy |
Latest AVDL news
About
Download (Excel)Mr. Gregory Divis
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.